These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way? Banerjee D, Stableforth D. Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122 [Abstract] [Full Text] [Related]
3. Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre. Manno G, Cruciani M, Romano L, Scapolan S, Mentasti M, Lorini R, Minicucci L. Int J Antimicrob Agents; 2005 Mar; 25(3):193-7. PubMed ID: 15737511 [Abstract] [Full Text] [Related]
4. Changes in strategies for optimal antibacterial therapy in cystic fibrosis. Ratjen F. Int J Antimicrob Agents; 2001 Feb; 17(2):93-6. PubMed ID: 11165111 [Abstract] [Full Text] [Related]
5. Pseudomonas colonization in cystic fibrosis. A study of 160 patients. Kulczycki LL, Murphy TM, Bellanti JA. JAMA; 1978 Jul 07; 240(1):30-4. PubMed ID: 96277 [Abstract] [Full Text] [Related]
6. Bacteriological effects of anti-Pseudomonas aeruginosa chemotherapy in cystic fibrosis. Bauernfeind A, Emminger G, Hörl G, Ott S, Przyklenk B, Weisslein-Pfister C. Infection; 1987 Jul 07; 15(5):403-6. PubMed ID: 3121519 [Abstract] [Full Text] [Related]
7. Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients. Rees VE, Yadav R, Rogers KE, Bulitta JB, Wirth V, Oliver A, Boyce JD, Peleg AY, Nation RL, Landersdorfer CB. Antimicrob Agents Chemother; 2018 Nov 07; 62(11):. PubMed ID: 30104278 [Abstract] [Full Text] [Related]
8. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis. Conway SP, Brownlee KG, Denton M, Peckham DG. Am J Respir Med; 2003 Nov 07; 2(4):321-32. PubMed ID: 14719998 [Abstract] [Full Text] [Related]
9. Does monotherapy of pulmonary infections in cystic fibrosis lead to early development of resistant strains of Pseudomonas aeruginosa? Watkins J, Francis J, Kuzemko JA. Scand J Gastroenterol Suppl; 1988 Nov 07; 143():81-5. PubMed ID: 3133756 [Abstract] [Full Text] [Related]
10. Rational parameters for antibiotic therapy in patients with cystic fibrosis. Govan JR, Doherty C, Glass S. Infection; 1987 Nov 07; 15(4):300-7. PubMed ID: 3117704 [Abstract] [Full Text] [Related]
11. Antimicrobials in cystic fibrosis: emergence of resistance and implications for treatment. Zabner R, Quinn JP. Semin Respir Infect; 1992 Sep 07; 7(3):210-7. PubMed ID: 1475544 [Abstract] [Full Text] [Related]
12. Antimicrobial susceptibility of microorganisms isolated from sputum culture of patients with cystic fibrosis: Methicillin-resistant Staphylococcus aureus as a serious concern. Mazloomi Nobandegani N, Mahmoudi S, Pourakbari B, Hosseinpour Sadeghi R, Najafi Sani M, Farahmand F, Motamed F, Nabavizadeh Rafsanjani R, Mamishi S. Microb Pathog; 2016 Nov 07; 100():201-204. PubMed ID: 27666507 [Abstract] [Full Text] [Related]
13. The approach to Pseudomonas aeruginosa in cystic fibrosis. Bendiak GN, Ratjen F. Semin Respir Crit Care Med; 2009 Oct 07; 30(5):587-95. PubMed ID: 19760546 [Abstract] [Full Text] [Related]
14. Emergence of ceftriaxone-resistant strains of Pseudomonas aeruginosa in cystic fibrosis patients. Paull A, Morgan JR. J Antimicrob Chemother; 1986 Nov 07; 18(5):635-9. PubMed ID: 3100487 [Abstract] [Full Text] [Related]
15. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Emerson J, McNamara S, Buccat AM, Worrell K, Burns JL. Pediatr Pulmonol; 2010 Apr 07; 45(4):363-70. PubMed ID: 20232473 [Abstract] [Full Text] [Related]
16. In-vitro investigation of the antibacterial activity of agents which may be used for the oral treatment of lung infections in CF patients. Richards RM, Hamilton VE, Thomas MR. J Antimicrob Chemother; 1998 Aug 07; 42(2):171-8. PubMed ID: 9738834 [Abstract] [Full Text] [Related]
17. Phenotypic shift in Pseudomonas aeruginosa populations from cystic fibrosis lungs after 2-week antipseudomonal treatment. Fernández-Barat L, Ciofu O, Kragh KN, Pressler T, Johansen U, Motos A, Torres A, Hoiby N. J Cyst Fibros; 2017 Mar 07; 16(2):222-229. PubMed ID: 27651273 [Abstract] [Full Text] [Related]
18. Increasing Incidence of Multidrug Resistance Among Cystic Fibrosis Respiratory Bacterial Isolates. Rutter WC, Burgess DR, Burgess DS. Microb Drug Resist; 2017 Jan 07; 23(1):51-55. PubMed ID: 27326758 [Abstract] [Full Text] [Related]
19. Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study. Connett GJ, Pike KC, Legg JP, Cathie K, Dewar A, Foote K, Harris A, Faust SN. Ther Adv Respir Dis; 2015 Dec 07; 9(6):272-80. PubMed ID: 26341118 [Abstract] [Full Text] [Related]
20. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1997)]. Ikemoto H, Ito C, Yoshida T, Watanabe K, Mori T, Ohno I, Okada S, Igari J, Arakawa M, Igarashi K, Oguri T, Okada M, Ozaki K, Terai T, Aoki N, Inoue H, Nakadate T, Kitamura N, Sekine O, Suzuki Y, Ando M, Suga M, Sato K, Nakata K, Kusano N. Jpn J Antibiot; 1999 May 07; 52(5):353-97. PubMed ID: 10480048 [Abstract] [Full Text] [Related] Page: [Next] [New Search]